These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30590590)

  • 81. High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease.
    Barnes EL; Long MD; Kappelman MD; Martin CF; Sandler RS
    Inflamm Bowel Dis; 2019 Jun; 25(7):1248-1254. PubMed ID: 30590700
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Interactions Between Autophagy and the Unfolded Protein Response: Implications for Inflammatory Bowel Disease.
    Hooper KM; Barlow PG; Henderson P; Stevens C
    Inflamm Bowel Dis; 2019 Mar; 25(4):661-671. PubMed ID: 30590697
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease.
    Arihiro S; Nakashima A; Matsuoka M; Suto S; Uchiyama K; Kato T; Mitobe J; Komoike N; Itagaki M; Miyakawa Y; Koido S; Hokari A; Saruta M; Tajiri H; Matsuura T; Urashima M
    Inflamm Bowel Dis; 2019 May; 25(6):1088-1095. PubMed ID: 30601999
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
    Panés J; D'Haens GR; Higgins PDR; Mele L; Moscariello M; Chan G; Wang W; Niezychowski W; Su C; Maller E
    Aliment Pharmacol Ther; 2019 Feb; 49(3):265-276. PubMed ID: 30663107
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 86. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
    Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Microbial network disturbances in relapsing refractory Crohn's disease.
    Yilmaz B; Juillerat P; Øyås O; Ramon C; Bravo FD; Franc Y; Fournier N; Michetti P; Mueller C; Geuking M; Pittet VEH; Maillard MH; Rogler G; ; Wiest R; Stelling J; Macpherson AJ
    Nat Med; 2019 Feb; 25(2):323-336. PubMed ID: 30664783
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
    Sands BE; Van Assche G; Tudor D; Akhundova-Unadkat G; Curtis RI; Tan T
    Inflamm Bowel Dis; 2019 Jul; 25(8):1375-1382. PubMed ID: 30615117
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.
    Panchal H; Wagner M; Chatterji M; Taouli B; McBride R; Patterson JR; Ungaro R; Dubinsky M; Cho J; Sachar DB
    Dig Dis Sci; 2019 Nov; 64(11):3274-3283. PubMed ID: 30607690
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
    Osterman MT; Rosario M; Lasch K; Barocas M; Wilbur JD; Dirks NL; Gastonguay MR
    Aliment Pharmacol Ther; 2019 Feb; 49(4):408-418. PubMed ID: 30663076
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
    Haberman Y; Karns R; Dexheimer PJ; Schirmer M; Somekh J; Jurickova I; Braun T; Novak E; Bauman L; Collins MH; Mo A; Rosen MJ; Bonkowski E; Gotman N; Marquis A; Nistel M; Rufo PA; Baker SS; Sauer CG; Markowitz J; Pfefferkorn MD; Rosh JR; Boyle BM; Mack DR; Baldassano RN; Shah S; Leleiko NS; Heyman MB; Grifiths AM; Patel AS; Noe JD; Aronow BJ; Kugathasan S; Walters TD; Gibson G; Thomas SD; Mollen K; Shen-Orr S; Huttenhower C; Xavier RJ; Hyams JS; Denson LA
    Nat Commun; 2019 Jan; 10(1):38. PubMed ID: 30604764
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.
    Choy MC; Seah D; Faleck DM; Shah SC; Chao CY; An YK; Radford-Smith G; Bessissow T; Dubinsky MC; Ford AC; Churilov L; Yeomans ND; De Cruz PP
    Inflamm Bowel Dis; 2019 Jun; 25(7):1169-1186. PubMed ID: 30605549
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus.
    Bouchard D; Pigot F; Staumont G; Siproudhis L; Abramowitz L; Benfredj P; Brochard C; Fathallah N; Faucheron JL; Higuero T; Panis Y; de Parades V; Vinson-Bonnet B; Laharie D
    Tech Coloproctol; 2018 Dec; 22(12):905-917. PubMed ID: 30604249
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Current new challenges in the management of ulcerative colitis.
    Fukuda T; Naganuma M; Kanai T
    Intest Res; 2019 Jan; 17(1):36-44. PubMed ID: 30678445
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Verstockt B; Verstockt S; Creyns B; Tops S; Van Assche G; Gils A; Ceuppens JL; Vermeire S; Ferrante M; Breynaert C
    Aliment Pharmacol Ther; 2019 Mar; 49(5):572-581. PubMed ID: 30663072
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.